CASI Pharmaceuticals (CASIF) Current Assets (2021 - 2025)
CASI Pharmaceuticals' (CASIF) quarterly Current Assets came in at $13.5 million in Q4 2025, down 66.0% YoY from $39.6 million in Q4 2024, and up 12.94% on a QoQ basis from $11.9 million in Q3 2025.
CASI Pharmaceuticals (CASIF) Current Assets (2021 - 2025) Analysis & Trends
CASI Pharmaceuticals (CASIF) has 5 years of Current Assets data on file, last reported at $13.5 million in Q4 2025.
- Quarterly Current Assets fell 66.0% year-over-year to $13.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $13.5 million (down 66.0% YoY) and the FY2025 annual result came in at $13.5 million, down 66.0% from the prior year.
- Current Assets grew to $13.5 million in Q4 2025, from $11.9 million in the prior quarter.
- In the past five years, Current Assets ranged from a high of $61.0 billion in Q2 2023 to a low of $11.9 million in Q3 2025.
- A 5-year average of $16.8 billion and a median of $62.0 million in 2021 frame the typical range for Current Assets.
- Annual changes were most pronounced in 2023 — Current Assets jumped 80724.81% — and 2025, when it plunged 99.95%.
- Tracing CASIF's Current Assets over 5 years: stood at $62.0 million in 2021, then increased by 18.48% to $73.4 million in 2022, then jumped by 80724.81% to $59.3 billion in 2023, then sank by 99.93% to $39.6 million in 2024, then tumbled by 66.0% to $13.5 million in 2025.
- The last three Current Assets figures came in at $13.5 million (Q4 2025), $11.9 million (Q3 2025), and $18.2 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.62 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 18.80 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.63 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 1.76 Bn |
| 10 | CASI Pharmaceuticals | 2.65 Mn | -3.76 Bn | - | 10.02 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 13.46 Mn |
| Sep 30, 2025 | 11.92 Mn |
| Jun 30, 2025 | 18.16 Mn |
| Mar 31, 2025 | 27.16 Bn |
| Dec 31, 2024 | 39.58 Mn |
| Jun 30, 2024 | 37.20 Bn |
| Mar 31, 2024 | 43.15 Mn |
| Dec 31, 2023 | 59.34 Bn |
| Jun 30, 2023 | 61.00 Bn |
| Dec 31, 2022 | 73.42 Mn |
| Dec 31, 2021 | 61.97 Mn |